These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12614037)

  • 61. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.
    Loudon JM; Bromidge SM; Brown F; Clark MS; Hatcher JP; Hawkins J; Riley GJ; Noy G; Orlek BS
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1059-68. PubMed ID: 9399977
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Juvenile Sjögren syndrome: distinctive age, unique findings.
    de Souza TR; Silva IH; Carvalho AT; Gomes VB; Duarte AP; Leão JC; Gueiros LA
    Pediatr Dent; 2012; 34(5):427-30. PubMed ID: 23211922
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Agonist potency ratios at m1 and m3 muscarinic receptors expressed in A9L and CHO cells.
    Richards MH
    Ann N Y Acad Sci; 1997 May; 812():165. PubMed ID: 9214278
    [No Abstract]   [Full Text] [Related]  

  • 64. Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque.
    Fitten LJ; Ortiz F; Siembieda DW; O'Neill J; Halgren E; Fisher A
    J Neuropsychiatry Clin Neurosci; 1999; 11(1):79-85. PubMed ID: 9990560
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the effects of pilocarpine and cevimeline on salivary flow.
    Braga MA; Tarzia O; Bergamaschi CC; Santos FA; Andrade ED; Groppo FC
    Int J Dent Hyg; 2009 May; 7(2):126-30. PubMed ID: 19416095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjögren's syndrome.
    Cavill D; Waterman SA; Gordon TP
    J Rheumatol; 2002 Jun; 29(6):1342-4. PubMed ID: 12064859
    [No Abstract]   [Full Text] [Related]  

  • 67. A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome.
    Gibson J; Halliday JA; Ewert K; Robertson S
    Br Dent J; 2007 Apr; 202(7):E17; discussion 404-5. PubMed ID: 17273177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.
    Wood MD; Murkitt KL; Ho M; Watson JM; Brown F; Hunter AJ; Middlemiss DN
    Br J Pharmacol; 1999 Apr; 126(7):1620-4. PubMed ID: 10323594
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 70. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.
    Hargreaves RJ; McKnight AT; Scholey K; Newberry NR; Street LJ; Hutson PH; Semark JE; Harley EA; Patel S; Freedman SB
    Br J Pharmacol; 1992 Oct; 107(2):494-501. PubMed ID: 1422595
    [TBL] [Abstract][Full Text] [Related]  

  • 71. M3 muscarinic acetylcholine receptor reactive IL-17 producing T cells promotes development of Sjögren's syndrome like sialadenitis.
    Iizuka M; Tsuboi H; Asashima H; Hirota T; Kondo Y; Matsui M; Matsumoto I; Sumida T
    Mod Rheumatol; 2015 Jan; 25(1):158-60. PubMed ID: 24593169
    [No Abstract]   [Full Text] [Related]  

  • 72. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
    Tomiita M; Takei S; Kuwada N; Nonaka Y; Saito K; Shimojo N; Kohno Y
    Mod Rheumatol; 2010 Oct; 20(5):486-90. PubMed ID: 20517630
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report.
    Acquarulo B; Tandon P; Macica CM
    J Med Case Rep; 2022 Jun; 16(1):253. PubMed ID: 35765109
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors.
    Pei XF; Gupta TH; Badio B; Padgett WL; Daly JW
    J Med Chem; 1998 Jun; 41(12):2047-55. PubMed ID: 9622546
    [TBL] [Abstract][Full Text] [Related]  

  • 75. M1 muscarinic receptor signaling in mouse hippocampus and cortex.
    Porter AC; Bymaster FP; DeLapp NW; Yamada M; Wess J; Hamilton SE; Nathanson NM; Felder CC
    Brain Res; 2002 Jul; 944(1-2):82-9. PubMed ID: 12106668
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
    Del Bello F; Bonifazi A; Quaglia W; Mazzolari A; Barocelli E; Bertoni S; Matucci R; Nesi M; Piergentili A; Vistoli G
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3255-9. PubMed ID: 24980056
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Abberant Sudomotor Functions in Sjögren's Syndrome: Comparable Study with Atopic Dermatitis on Dry Skin Manifestation.
    Katayama I
    Curr Probl Dermatol; 2016; 51():62-74. PubMed ID: 27584964
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does autonomic nervous impairment have a role in pathophysiology of Sjögren's syndrome.
    Hakala M; Niemelä RK
    Lancet; 2000 Mar; 355(9209):1032-3. PubMed ID: 10744085
    [No Abstract]   [Full Text] [Related]  

  • 79. Are autoantibodies against a 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor a new diagnostic marker for Sjögren's syndrome?
    Zigon P; Bozic B; Cucnik S; Rozman B; Tomsic M; Kveder T
    Ann Rheum Dis; 2005 Aug; 64(8):1247; author reply 1247. PubMed ID: 16014696
    [No Abstract]   [Full Text] [Related]  

  • 80. Nitric oxide-dependent relaxation induced by M1 muscarinic receptor activation in the rat small intestine.
    Olgart C; Iversen HH
    Br J Pharmacol; 1999 May; 127(1):309-13. PubMed ID: 10369487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.